Keywords: aventis/p, claim, superiority, actonel, over, merck, co
Aventis/P&G claim superiority of Actonel over Merck & Co's Fosamax
Article | 25 September 2000
Aventis/Procter & Gamble's bisphosphonate drug Actonel (risedronate) isassociated with fewer gastric ulcers in healthy postmenopausal women than the market leader, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
